Spinifex Pharmaceuticals is a technology company.
Spinifex Pharmaceuticals has raised $76.0M across 4 funding rounds.
Spinifex Pharmaceuticals has raised $76.0M in total across 4 funding rounds.
The premise of your query contains an inaccuracy: Spinifex Pharmaceuticals is not a technology company—it is a biotechnology company focused on pharmaceutical development.
Spinifex Pharmaceuticals is a US-Australian biotechnology company developing novel drug candidates for pain management, with a particular focus on neuropathic pain treatment.[1] The company was established in 2005 and based in Melbourne, Australia, operating as a privately held development-stage firm.[3][4]
The company's core mission centers on addressing a significant unmet medical need in pain treatment. Neuropathic pain is a chronic, debilitating condition affecting millions globally, with approximately 40% of patients failing to respond to current first-line treatments.[2] Spinifex's approach differs from conventional pain medications by developing peripheral treatments that work outside the blood-brain barrier, potentially avoiding central nervous system side effects that plague existing therapies.
Spinifex Pharmaceuticals was established in June 2005 in Melbourne as a private drug development company.[3] The company emerged from a focus on developing innovative approaches to treat neuropathic pain—a chronic condition with limited effective treatment options. The company's lead candidate, EMA401, represents a novel angiotensin II Type 2 receptor (AT2R) antagonist designed specifically for peripheral pain management.[2]
A pivotal moment came when positive Phase II clinical trial results for EMA401 in post-herpetic neuralgia (a painful complication of shingles) were published in *The Lancet*, demonstrating efficacy without central nervous system side effects or serious adverse events.[2] This validation of the compound's safety and efficacy profile attracted significant attention from major pharmaceutical players.
Spinifex represents the biotechnology sector's ongoing effort to develop more targeted, mechanism-based treatments for chronic pain—a major public health challenge. The company's peripheral approach aligns with broader industry trends toward precision medicine and reducing adverse effects through selective drug targeting. The validation of EMA401 in clinical trials demonstrated that novel receptor targets could address treatment-resistant pain conditions, influencing how the pharmaceutical industry approaches pain management development.
In June 2015, Novartis acquired Spinifex Pharmaceuticals, integrating the company's pipeline into its industry-leading development portfolio.[2] This acquisition reflected Novartis's strategic interest in advancing EMA401 through later-stage clinical development and commercialization, positioning the compound within a global pharmaceutical infrastructure capable of bringing innovative pain treatments to market worldwide.
Spinifex Pharmaceuticals has raised $76.0M in total across 4 funding rounds.
Spinifex Pharmaceuticals's investors include Brandon Capital Partners, Canaan Partners, Red Tree Venture Capital.
Spinifex Pharmaceuticals has raised $76.0M across 4 funding rounds. Most recently, it raised $45.0M Series C in April 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2014 | $45.0M Series C | Brandon Capital Partners, Canaan Partners, Red Tree Venture Capital | |
| Aug 1, 2011 | $19.0M Series B | Brandon Capital Partners | |
| Sep 1, 2008 | $10.0M Series A | Brandon Capital Partners | |
| Jul 1, 2005 | $2.0M Series A | Brandon Capital Partners |